A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 100
- Population
- ALL · 65 Years
- Duration
- 2026-09-01 to 2028-02-01
- Intervention
- IN-207907 120 mg; IN-207907 240 mg; IN-207907 360 mg; Placebo
- Comparator
- Placebo
- Outcomes measured
- Change in the Short Physical Performance Battery (SPPB) total score — From baseline to week 12; Change in the Short Physical Performance Battery (SPPB) total score — From baseline to week 4 and 8; Change in time to complete the 4-Meter Walk Test (4MWT) — From baseline to week 4, 8 and 12; Change in time to complete the 5 Times Chair Stand Test — From baseline to week 4, 8 and 12; Change in time to complete the Timed Up and Go (TUG) test — From baseline to week 4, 8 and 12; Change in handgrip strength measured using a digital hand dynamometer — From baseline to week 4, 8 and 12; Change in Appendicular Skeletal muscle Mass (ASM) as measured by Dual-energy X-ray Absorptiometry (DEXA) — From baselin…; Change in the total score of the Strength, Assistance with walking, Rise from a chair, Climb stairs, and Falls (SARC-F)…; Change in the total score of the Sarcopenia Quality of Life (SarQoL) questionnaire — From baseline to week 12; Change in proportion of FoxP3+ regulatory T cells — From baseline to week 4, 8 and 12; Change in serum interleukin-6 (IL-6) concentration — From baseline to week 4, 8 and 12; Change in serum insulin-like growth factor-1 (IGF-1) concentration — From baseline to week 4, 8 and 12; Change in high-sensitivity C-reactive protein (hs-CRP) level — From baseline to week 4, 8 and 12; Exercise and dietary compliance rate — From baseline to week 4, 8 and 12
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Sarcopenia · 100%Title contains controlled term: sarcopenia. Abstract contains controlled term: sarcopenia. Source terminology contains: sarcopenia. Title supplies longevity context: elderly. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.